UBT251, a novel triple GLP-1, GIP, and glucagon receptor agonist, in adults with type 2 diabetes: A multicenter, randomized phase 2 trial.

In 211 Chinese adults with type 2 diabetes, once-weekly UBT251 lowered glycated hemoglobin by -2.16% to -1.98% at week 24 versus -0.66% with placebo.

• Why it matters: Better glucose control and weight reduction are needed for type 2 diabetes beyond existing therapies, motivating evaluation of a triple GLP-1, GIP, and glucagon agonist.
• What they did: In a multicenter randomized phase 2 trial, participants received UBT251 (2 mg, 4 mg with initial dose 0.5 mg or 1 mg, or 6 mg), 1 mg semaglutide, or placebo for 24 weeks.
• The result: UBT251 significantly reduced fasting and 2-h postprandial glucose and waist circumference versus placebo (all p < 0.001) and produced greater weight reduction than both placebo and semaglutide (all p < 0.05), with gastrointestinal events most common.